Our Achievements - TILs or Tumor Infiltrating Lymphocytes скачать в хорошем качестве

Our Achievements - TILs or Tumor Infiltrating Lymphocytes

Research has shown that a higher number of TILs detected in a patient’s tumour, is associated with better outcomes and indicates the patient’s immune system is rallying a response to their cancer. This is particularly so for patients with triple negative breast cancer and HER2 positive breast cancer – two of the most aggressive sub-types of breast cancer. Professor Sherene Loi, Board Director and Breast Cancer Trials researcher, has a strong interest in biomarker development as this can help us manage patients better. She has led the development and implementation of the TILs biomarker in breast cancer and has led a number of immunotherapy studies that have been conducted by Breast Cancer Trials – the PANACEA, NEO-N and DIAmOND clinical trials. ---------------------------------------------------------------- Breast Cancer Trials is a group of world-leading breast cancer doctors and researchers based in Australia and New Zealand committed to exploring and finding better treatments for people affected by breast cancer through clinical trials research. Please like this video then visit www.breastcancertrials.org.au to find out more about our current breast cancer clinical trials that may be suitable for you, and ways in which you can help support breast cancer research. ---------------------------------------------------------------- SUBSCRIBE TO OUR YOUTUBE CHANNEL    / @breastcancertrials   LET'S CONNECT Email ►[email protected] Tel 1800 423 444 WWW ► http://www.breastcancertrials.org.au Linkedin ►   / 5057154   Twitter ►   / bctrialsanz   Facebook ►   / breastcancertrials   Instagram ►   / breastcancertrials